Royalty Pharma (RPRX) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

RPRX Royalty Pharma

Watchlist

26.400
+0.180+0.69%

Close Nov 21 16:00 ET

26.480
+0.080+0.30%

Post 16:59 ET

11.73BMarket Cap10.39P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $39
Moomoo NewsNov 19 09:31 ET · Ratings
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $39
Moomoo NewsNov 19 07:31 ET · Ratings
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
TipRanksNov 19 06:46 ET · Ratings
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
GlobeNewswireNov 14 16:30 ET
Royalty Pharma To Go Ex-Dividend On November 15th, 2024 With 0.21 USD Dividend Per Share
Moomoo NewsNov 13 20:00 ET
Royalty Pharma's (NASDAQ:RPRX) Solid Earnings May Rest On Weak Foundations
Simply Wall StNov 13 07:03 ET

Comments

Trytosaveabit

Nov 4 15:05

News

$Syndax Pharmaceuticals (SNDX.US)$ $Royalty Pharma (RPRX.US)$ Press Release: Syndax Pharmaceuticals and Royalty Pharma Enter Into $350 Million Royalty Funding Agreement for Niktimvo(TM)
Dow Jones· 1 min ago

Moomoo AI

Feb 22 04:36

Unusual items boosting Royalty Pharma's profit may not recur, possibly causing a profit drop this year. The company's statutory earnings may not truly reflect its underlying earnings power. Investors should note 4 warning signs for Royalty Pharma.

There May Be Underlying Issues With The Quality Of Royalty Pharma's (NASDAQ:RPRX) Earnings

Moomoo AI

Dec 18, 2023 05:24

Significant insider share selling might worry some shareholders despite the implication of the company acting in all shareholders' interest. The overall analysis of insider transactions, however, lacks confidence.